Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody

BACKGROUND: Aberrant MET tyrosine kinase signaling is known to cause cancer initiation and progression. While MET inhibitors are in clinical trials against several cancer types, the clinical efficacies are controversial and the molecular mechanisms toward sensitivity remain elusive. METHODS: With th...

Descripción completa

Detalles Bibliográficos
Autores principales: Kou, Jianqun, Musich, Phillip R., Staal, Ben, Kang, Liang, Qin, Yuan, Yao, Zhi Q., Zhang, Boheng, Wu, Weizhong, Tam, Angela, Huang, Alan, Hao, Huai-Xiang, Vande Woude, George F., Xie, Qian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134500/
https://www.ncbi.nlm.nih.gov/pubmed/30208970
http://dx.doi.org/10.1186/s12967-018-1628-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134500/
https://www.ncbi.nlm.nih.gov/pubmed/30208970
http://dx.doi.org/10.1186/s12967-018-1628-y

Ejemplares similares